STAT6-mediated BCL6 repression in primary mediastinal B-cell lymphoma (PMBL)

Oncotarget

Volumn 4, Issue 7, 2013, Pages 1093-1102

  Ritz, Olga ^a   Rommel, Karolin ^b   Dorsch, Karola ^a   Kelsch, Elena ^a   Melzner, Julia ^a   Buck, Michaela ^a   Leroy, Karen ^c   Papadopoulou, Vasiliki ^d   Wagner, Simon ^d   Marienfeld, Ralf ^a   Brüderlein, Silke ^a   Lennerz, Jochen K ^a   Möller, Peter ^a  

^a UNIVERSITY OF ULM   (Germany)

^b INSTITUTE FOR RESEARCH IN BIOMEDICINE   (Switzerland)

^c HENRI MONDOR HOSPITAL   (France)

^d UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

BCL6; Intratumoral heterogeneity; PMBL; pSTAT6

Indexed keywords

JANUS KINASE; JANUS KINASE 2; PROTEIN BCL 6; SMALL INTERFERING RNA; STAT6 PROTEIN;

ARTICLE; B CELL LYMPHOMA; BINDING SITE; CELL VIABILITY; CHROMATIN IMMUNOPRECIPITATION; FLUORESCENCE ANALYSIS; GENE EXPRESSION; GENE TARGETING; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LYMPHOMA CELL; PRIMARY MEDIASTINAL B CELL LYMPHOMA; PROMOTER REGION; PROTEIN BINDING; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

CELL LINE, TUMOR; DNA-BINDING PROTEINS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPHOMA, B-CELL; MEDIASTINAL NEOPLASMS; SIGNAL TRANSDUCTION; STAT6 TRANSCRIPTION FACTOR; TRANSFECTION;

EID: 84884260608     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.1149     Document Type: Article

References (52)

1. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, and Vardiman JW. World Health Organization Classification of Tumours of Hematopoietic and Lymphoid Tisues. (4th edition). 2008; Lyon, IARC press. Ref Type: Generic
2. Feuerhake F, Kutok JL, Monti S, Chen W, LaCasce AS, Cattoretti G, Kurtin P, Pinkus GS, de,Leval L, Harris NL, Savage KJ, Neuberg D, Habermann TM, Della-Favera R, Golub TR, Aster JC, Shipp MA. NFkappaB activity, function, and target-gene signatures in primary mediastinal large B-cell lymphoma and diffuse large B-cell lymphoma subtypes. Blood. 2005;106:1392-1399.
3. Rosenwald A, Wright G, Leroy K, Yu X, Gaulard P, Gascoyne RD, Chan WC, Zhao T, Haioun C, Greiner TC, Weisenburger DD, Lynch JC, Vose J, Armitage JO, Smeland EB, Kvaloy S, et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J. Exp. Med. 2003; 198: 851-862.
4. Moller P, Lammler B, Eberlein-Gonska M, Feichter GE, Hofmann WJ, Schmitteckert H, Otto HF. Primary mediastinal clear cell lymphoma of B-cell type. Virchows Arch. A Pathol. Anat. Histopathol. 1986; 409: 79-92.
5. Moller P, Moldenhauer G, Momburg F, Lammler B, Eberlein-Gonska M, Kiesel S, Dorken B. Mediastinal lymphoma of clear cell type is a tumor corresponding to terminal steps of B cell differentiation. Blood. 1987; 69: 1087-1095.
6. Melzner I, Weniger MA, Menz CK, Moller P. Absence of the JAK2 V617F activating mutation in classical Hodgkin lymphoma and primary mediastinal B-cell lymphoma. Leukemia. 2006; 20: 157-158.
7. Rui L, Emre NC, Kruhlak MJ, Chung HJ, Steidl C, Slack G, Wright GW, Lenz G, Ngo VN, Shaffer AL, Xu W, Zhao H, Yang Y, Lamy L, Davis RE, XiaoW, et al. Cooperative epigenetic modulation by cancer amplicon genes. Cancer Cell. 2010; 18: 590-605.
8. Melzner I, Bucur A.J, Bruderlein S, Dorsch K, Hasel C, Barth TF, Leithauser F, Moller P. Biallelic mutation of SOCS-1 impairs JAK2 degradation and sustains phospho-JAK2 action in the MedB-1 mediastinal lymphoma line. Blood. 2005; 105: 2535-2542.
9. Melzner I, Weniger MA, Bucur AJ, Bruderlein S, Dorsch K, Hasel C, Leithauser F, Ritz O, Dyer MJ, Barth T F, Moller P. Biallelic deletion within 16p13.13 including SOCS-1 in Karpas1106P mediastinal B-cell lymphoma line is associated with delayed degradation of JAK2 protein. Int. J. Cancer. 2006; 118: 1941-1944.
10. Guiter C, Dusanter-Fourt I, Copie-Bergman C, Boulland ML, Le GS, Gaulard P, Leroy K, Castellano F. Constitutive STAT6 activation in primary mediastinal large B-cell lymphoma. Blood. 2004; 104: 543-549.
11. De Leval L, Ferry JA, Falini B, Shipp M, Harris N L. Expression of bcl-6 and CD10 in primary mediastinal large B-cell lymphoma: evidence for derivation from germinal center B cells? Am. J. Surg. Pathol. 2001; 25; 1277-1282.
12. Malpeli G, Barbi S, Moore PS, Scardoni M, Chilosi M, Scarpa A, Menestrina F. Primary mediastinal B-cell lymphoma: hypermutation of the BCL6 gene targets motifs different from those in diffuse large B-cell and follicular lymphomas. Haematologica. 2004; 89:1091-1099.
13. Palanisamy,N, Abou-Elella AA, Chaganti, S.R, Houldsworth,J, Offit, K, Louie, D.C, Terayu-Feldstein,J, Cigudosa,J.C, Rao,P.H, Sanger,W.G, Weisenburger,D.D. and Chaganti,R.S. (2002) Similar patterns of genomic alterations characterize primary mediastinal large-B-cell lymphoma and diffuse large-B-cell lymphoma. Genes Chromosomes. Cancer, 33, 114-122.
14. Cattoretti G, Pasqualucci L, Ballon G, Tam W, Nandula SV, Shen Q, Mo T, Murty VV, Dalla-Favera R. Deregulated BCL6 expression recapitulates the pathogenesis of human diffuse large B cell lymphomas in mice. Cancer Cell. 2005;7: 445-455.
15. Cerchietti LC, Ghetu AF, Zhu X, Da Silva GF, Zhong S, Matthews M, Bunting KL, Polo JM, Fares C, Arrowsmith CH, Yang SN, Garcia M, Coop A, Mackerell AD, Jr, Prive GG, Melnick A. A small-molecule inhibitor of BCL6 kills DLBCL cells in vitro and in vivo. Cancer Cell. 2010; 17: 400-411.
16. Polo JM, Dell'Oso T, Ranuncolo SM, Cerchietti L, Beck D, Da Silva GF, Prive GG, Licht JD, Melnick A. Specific peptide interference reveals BCL6 transcriptional and oncogenic mechanisms in B-cell lymphoma cells. Nat.Med. 2004; 10: 1329-1335.
17. Kolonic SO, Dzebro S, Kusec R, Planinc-Peraica A, Dominis M, Jaksic B. Primary mediastinal large B-cell lymphoma: a single-center study of clinicopathologic characteristics. Int.J.Hematol. 2006; 83: 331-336.
18. Moller P, Bruderlein S, Strater J, Leithauser F, Hasel C, Bataille F, Moldenhauer G, Pawlita M, Barth TF. MedB-1, a human tumor cell line derived from a primary mediastinal large B-cell lymphoma. Int.J.Cancer. 2001; 92: 348-353.
19. Nacheva E, Dyer MJ, Metivier C, Jadayel D, Stranks G, Morilla R, Heward JM, Holloway T, O'Connor S, Bevan PC. B-cell non-Hodgkin's lymphoma cell line (Karpas 1106) with complex translocation involving 18q21.3 but lacking BCL2 rearrangement and expression. Blood. 1994; 84: 3422-3428.
20. Sambade C, Berglund M, Lagercrantz S, Sallstrom J, Reis RM, Enblad G, Glimelius B, Sundstrom C. U-2940, a human B-cell line derived from a diffuse large cell lymphoma sequential to Hodgkin lymphoma. Int.J.Cancer. 2004; 118: 555-563.
21. Goenka S, Kaplan MH. Transcriptional regulation by STAT6. Immunol.Res. 2011; 50: 87-96.
22. Dent AL, Shaffer AL, Yu X, Allman D, Staudt LM. Control of inflammation, cytokine expression, and germinal center formation by BCL-6. Science 1997; 276: 589-592.
23. Walker SR, Nelson EA, Frank DA. STAT5 represses BCL6 expression by binding to a regulatory region frequently mutated in lymphomas. Oncogene. 2007; 26:224-233.
24. Pasqualucci L, Migliazza A, Basso K, Houldsworth J, Chaganti RS, Dalla-Favera R. Mutations of the BCL6 proto-oncogene disrupt its negative autoregulation in diffuse large B-cell lymphoma. Blood. 2003; 101: 2914-2923.
25. Migliazza A, Martinotti S, Chen W, Fusco C, Ye BH, Knowles DM, Offit K, Chaganti RS, Dalla-Favera R. Frequent somatic hypermutation of the 5' noncoding region of the BCL6 gene in B-cell lymphoma. Proc.Natl.Acad.Sci.U.S.A. 1995; 92: 12520-12524.
26. Papadopoulou V, Postigo A, Sanchez-Tillo E, Porter AC, Wagner SD. ZEB1 and CtBP form a repressive complex at a distal promoter element of the BCL6 locus. Biochem.J. 2010; 427: 541-550.
27. Batlle A, Papadopoulou V, Gomes AR, Willimott S, Melo JV, Naresh K, Lam EW, Wagner S.D. CD40 and B-cell receptor signalling induce MAPK family members that can either induce or repress Bcl-6 expression. Mol.Immunol. 2009; 46: 1727-1735.
28. Ritz O, Guiter C, Dorsch K, Dusanter-Fourt I, Wegener S, Jouault H, Gaulard P, Castellano F, Moller P, Leroy K. STAT6 activity is regulated by SOCS-1 and modulates BCL-XL expression in primary mediastinal B-cell lymphoma. Leukemia. 2008; 22: 2106-2110.
29. Daniel C, Salvekar A, Schindler U. A gain-of-function mutation in STAT6. J.Biol.Chem. 2000; 275: 14255-14259.
30. Basso K, Dalla-Favera R. BCL6: master regulator of the germinal center reaction and key oncogene in B cell lymphomagenesis. Adv.Immunol. 2010; 105: 193-210.
31. Wagner SD, Ahearne M, Ferrigno P.K. The role of BCL6 in lymphomas and routes to therapy. Br.J.Haematol. 2011; 152: 3-12.
32. Weinstein IB. Cancer. Addiction to oncogenes--the Achilles heal of cancer. Science. 2002; 297: 63-64.
33. Bentz M, Barth TF, Bruderlein S, Bock D, Schwerer MJ, Baudis M, Joos S, Viardot A, Feller AC, Muller-Hermelink HK, Lichter P, Dohner H, Moller P. Gain of chromosome arm 9p is characteristic of primary mediastinal B-cell lymphoma (MBL): comprehensive molecular cytogenetic analysis and presentation of a novel MBL cell line. Genes Chromosomes. Cancer. 2001; 30: 393-401.
34. Schroder AJ, Pavlidis P, Arimura A, Capece D, Rothman PB. Cutting edge: STAT6 serves as a positive and negative regulator of gene expression in IL-4-stimulated B lymphocytes. J.Immunol. 2002; 168: 996-1000.
35. Scheeren FA, Naspetti M, Diehl S, Schotte R, Nagasawa M, Wijnands E, Gimeno R, Vyth-Dreese FA, Blom B, Spits H. STAT5 regulates the self-renewal capacity and differentiation of human memory B cells and controls Bcl-6 expression. Nat.Immunol. 2005; 6: 303-313.
36. Constantinescu SN, Girardot M, Pecquet C. Mining for JAK-STAT mutations in cancer. Trends Biochem.Sci. 2008; 33: 122-131.
37. Baus D, Nonnenmacher F, Jankowski S, Doring C, Brautigam C, Frank M, Hansmann ML, Pfitzner E. STAT6 and STAT1 are essential antagonistic regulators of cell survival in classical Hodgkin lymphoma cell line. Leukemia. 2009; 23: 1885-1893.
38. Elo LL, Jarvenpaa H, Tuomela S, Raghav S, Ahlfors H, Laurila K, Gupta B, Lund RJ, Tahvanainen J, Hawkins RD, Oresic M, Lahdesmaki H, Rasool O, Rao KV, Aittokallio T, Lahesmaa,R. Genome-wide profiling of interleukin-4 and STAT6 transcription factor regulation of human Th2 cell programming. Immunity. 2010; 32: 852-862.
39. Wei L, Vahedi G, Sun,H.W, Watford WT, Takatori H, Ramos H.L, Takahashi H, Liang J, Gutierrez-Cruz G, Zang C, Peng W, O'Shea, JJ, Kanno Y. Discrete roles of STAT4 and STAT6 transcription factors in tuning epigenetic modifications and transcription during T helper cell differentiation. Immunity. 2010; 32: 840-851.
40. Ritz O, Guiter C, Castellano F, Dorsch K, Melzner J, Jais JP, Dubois G, Gaulard P, Moller P, Leroy K. Recurrent mutations of the STAT6 DNA binding domain in primary mediastinal B-cell lymphoma. Blood. 2009; 114: 1236-1242.
41. Hartatik T, Okada S, Okabe S, Arima M, Hatano M, Tokuhisa,T. Binding of BAZF and Bc16 to STAT6-binding DNA sequences. Biochem. Biophys.Res.Commun. 2001; 284: 26-32.
42. Steidl C, Gascoyne RD. The molecular pathogenesis of primary mediastinal large B-cell lymphoma. Blood. 2011;118: 2659-2669.
43. Weinstein IB. Disorders in cell circuitry during multistage carcinogenesis: the role of homeostasis. Carcinogenesis. 2000; 21: 857-864.
44. Weinstein IB, Joe AK. Mechanisms of disease: Oncogene addiction--a rationale for molecular targeting in cancer therapy. Nat.Clin.Pract.Oncol. 2006; 3: 448-457.
45. Michor F, Polyak K. The origins and implications of intratumor heterogeneity. Cancer Prev.Res.(Phila). 2010; 3:1361-1364.
46. Ichim CV, Wells RA. First among equals: the cancer cell hierarchy. Leuk.Lymphoma. 2006; 47:, 2017-2027.
47. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature. 2001; 414: 105-111.
48. Almendro V, Marusyk A, Polyak,K. Cellular heterogeneity and molecular evolution in cancer. Annu.Rev.Pathol. 2013; 8: 277-302.
49. Lennerz JK, Kim SH, Oates EL, Huh WJ, Doherty JM, Tian X, Bredemeyer AJ, Goldenring JR, Lauwers GY, Shin YK, Mills JC. The transcription factor MIST1 is a novel human gastric chief cell marker whose expression is lost in metaplasia, dysplasia, and carcinoma. Am.J.Pathol. 2010; 177: 1514-1533.
50. Ushmorov A, Ritz O, Hummel M, Leithauser F, Moller P, Stein H, Wirth T. Epigenetic silencing of the immunoglobulin heavy-chain gene in classical Hodgkin lymphoma-derived cell lines contributes to the loss of immunoglobulin expression. Blood. 2004; 104: 3326-3334.
51. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001; 25: 402-408.
52. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001; 29: e45.